Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Imatinib Teva

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Imatinib Testmiljö

Imatinib

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005;19(6):984-9.

  2. Mandal R, Bolt DM, Shah BK. Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US. Acta Oncol. 2013;52(4):837-41.

  3. Chiang NJ, Chen LT, Tsai CR, Chang JS. The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998-2008: a nation-wide cancer registry-based study. BMC Cancer. 2014;14:102.

  4. van der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, de Wilt JHW. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. Br J Surg. 2018;105(8):1020-1027.

  5. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8(10):3034-8.

  6. Lin HX, Sjaarda J, Dyck J, Stringer R, Hillis C, Harvey M et al. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia. Eur J Haematol. 2016;96(4):360-6.

  7. Vasconcelos FC, Bonecker ST, de Souza PS, Scheiner MAM, Amaral N, Zalcberg I et al. Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients. Leuk Res. 2019;82:33-35.

  8. Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19):3818-24.

  9. Breccia M, Colafigli G, Molica M, De Angelis F, Quattrocchi L, Latagliata R et al. Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib. Br J Haematol. 2016;173(6):945-6.

  10. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232-8.

  11. Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre JM, Bui-Nguyen B et al. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer. 2016;52:173-80.

  12. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553-61.

  13. Ren X, Qin Y, Huang X, Zuo L, Jiang Q. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. Ann Hematol. 2019;98(7):1627-1640.

  14. Glivec (imatinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2022-03-22, cited 2022-05-18]

  15. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]

  1. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005;19(6):984-9.
  2. Mandal R, Bolt DM, Shah BK. Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US. Acta Oncol. 2013;52(4):837-41.
  3. Chiang NJ, Chen LT, Tsai CR, Chang JS. The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998-2008: a nation-wide cancer registry-based study. BMC Cancer. 2014;14:102.
  4. van der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, de Wilt JHW. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. Br J Surg. 2018;105(8):1020-1027.
  5. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8(10):3034-8.
  6. Lin HX, Sjaarda J, Dyck J, Stringer R, Hillis C, Harvey M et al. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia. Eur J Haematol. 2016;96(4):360-6.
  7. Vasconcelos FC, Bonecker ST, de Souza PS, Scheiner MAM, Amaral N, Zalcberg I et al. Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients. Leuk Res. 2019;82:33-35.
  8. Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19):3818-24.
  9. Breccia M, Colafigli G, Molica M, De Angelis F, Quattrocchi L, Latagliata R et al. Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib. Br J Haematol. 2016;173(6):945-6.
  10. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232-8.
  11. Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre JM, Bui-Nguyen B et al. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer. 2016;52:173-80.
  12. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553-61.
  13. Ren X, Qin Y, Huang X, Zuo L, Jiang Q. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. Ann Hematol. 2019;98(7):1627-1640.
  14. Glivec (imatinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2022-03-22, cited 2022-05-18]
  15. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]